- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Article
Inerferon may cure BCCs
Injections of interferon directly into the lesion may provide cures for a large portion of patients with basal cell carcinoma (BCC), according to a report in the June issue of the Journal of the American Academy of Dermatology.
Injections of interferon directly into the lesion may provide cures for a large portion of patients with basal cell carcinoma (BCC), according to a report in the June issue of the Journal of the American Academy of Dermatology.
Researchers in Houston evaluated injection of interferon in 50 patients with a total of 98 BCCs, treated from 1985 to 1992. At an average follow-up of 13.5 years (10 years minimum), cures were achieved in 95 of the 98 lesions.
Related Videos
Efficacy, Safety, and Role in Therapy of JAK Inhibitors for Atopic Dermatitis
The Impact of JAK Selectivity in Atopic Dermatitis Treatment
Recapping the Evolving Treatment Landscape for Atopic Dermatitis
Sunscreen Ingredients for UV and Visible Light Protection
The Solar Spectrum and Impact on Skin Health
Discussing Efficacy and Safety of JAK Inhibitors With Patients and Caregivers
Patient Considerations for Selecting Treatment for a 16-Year-Old Male With Severe Alopecia Areata
Future Directions for Pediatric Atopic Dermatitis Management and Research
New Systemic Therapies for Pediatric Atopic Dermatitis: Nemolizumab and Oral JAK Inhibitors
The JAK-STAT Signaling Pathway and Its Role in Atopic Dermatitis
Related Content
